Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesEULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis
Annals of Rheumatic Diseases, 10/12/09
Peters MJL et al. – Ten recommendations were made for CV risk management in patients with RA, AS and PsA. The strength of the recommendations differed between RA on the one hand, and AS and PsA on the other hand, as evidence for an increased CV risk is most compelling for RA.
Methods- A multidisciplinary expert committee convened as task force of EULAR Standing Committee for Clinical Affairs (ESCCA), comprising 18 members including rheumatologists, cardiologists, internists and epidemiologists, representing 9 European countries
- Problem areas and related keywords for systematic literature research identified
- Systematic literature research performed using MedLine, Embase and Cochrane library through to May 2008
- Based on literature review and in accordance with EULAR's 'standardised operating procedures', the multidisciplinary steering committee formulated evidence-based and expert opinion based recommendations for CV risk screening and management in patients with inflammatory arthritis
- Annual CV risk assessment using National Guidelines recommended for RA patients and should be considered for all AS and PsA patients
- CV risk factors identified should be managed according to local guidelines
- In addition to appropriate CV risk management, aggressive suppression of inflammatory process is recommended to further lower CV risk
Today in Other Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis
Rheumatology International, 10/26/09
The beneficial effects of a 3 week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: Results of the STIVEA trial
Annals of Rheumatic Diseases, 10/23/09
Hepatoprotective effect of TNF-alpha blockade in psoriatic arthritis: A cross-sectional study
Annals of Rheumatic Diseases, 11/09/09
Today in Rheumatoid Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
Treatment of polymyalgia rheumatica
Archives of Internal Medicine, 11/10/09
Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor [alpha] therapies: Does the risk change with the time since start of treatment?
Arthritis & Rheumatism, 11/05/09
Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study
Arthritis Care and Research , 11/03/09
Sponsor
Article Search
Sponsor